The takeaway
Damora Therapeutics, Inc. shows a pronounced seasonal pattern over 6 years of data — strongest in June (+6.7%) and softest in April (−12.4%).
Right now
In July, the stock has risen 40% of years, averaging +4.0%, about +1.8 pts better than the S&P 500.
The full picture
Damora Therapeutics, Inc.'s most dependable month has been June, higher in 3 of 5 years; April has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | — | — | — | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in November (+19.1 pts); it has trailed the market most in April (−14.0 pts).
“vs S&P” is Damora Therapeutics, Inc.’s average for a month minus the S&P 500’s average for that same month — isolating Damora Therapeutics, Inc.’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, June has closed higher 60% of the time versus 60% across the last 6 years — the pattern is holding.
Figures are the typical (median) June return and how often it rose — the last 5 years versus the last 6(the heatmap’s default window). This verdict stays anchored to that 6-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
There's a real but measured seasonal tilt here, toward June — the firmest corner of the calendar, higher in 3 of 5 Junes.
The strength looks broad-based rather than freakish: its average (+6.7%) and median (+6.6%) sit close together, so no single blow-out year is flattering the figure. That reliability comes with real swings, mind — even June ranges by 18.8% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — June has outpaced the S&P 500 by +6.5 points on average.
Only September comes anywhere near it for reliability. The weaker half of the year is plainer: April has been the soft spot — the weakest of 5 months that average a loss (−12.4%), and the edge isn't year-round — the stock has trailed the S&P 500 in April, March, and August. Its roughest month on record was a −78.4% August in 2023 — a reminder of how hard even a seasonal name can fall.
Treat it as a tendency rather than a rule — seasonality describes the past, not a promise. With a short 6-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (June), its worst (April), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2020 its best month (June, +6.7%) has run well ahead of its worst (April, −12.4%) — the heatmap above shows how steady that gap has been year to year.
June has been the strongest, averaging +6.7% and closing higher in 3 of 5 years since 2020.
It's the weakest, averaging −12.4% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade